ELEPSIA XR
· Patent Litigation & Settlement History ↓
Current GenericRadar decision
Discontinued in the 2026-10-10 product snapshot. The actual discontinuation date is unverified; retain NULL date and year.
2026-10-23 verification: FDA Orange Book September 2023 cumulative supplement, page 22, NDA 204417 product 001: DISC listed. 2023 denotes documented FDA DISC listing year, NOT confirmed actual cessation date. FDA evidence: https://www.fda.gov/media/173024/download
Patent estate
| Patent | Effective date | Official listing | TRUE_DS | DS grade | Claim classification / basis | PTE | PED | Family |
|---|---|---|---|---|---|---|---|---|
| 8425938 | 2026-02-22 | DP — | N | N | FORMULATION_OR_PK | — | — | — |
| 8425938 | 2026-02-22 | DP — | N | N | FORMULATION_OR_PK Limited to levetiracetam 55-90%, a compact high-dose tablet, and permeable coating. | — | — | — |
| 8535717 | 2026-02-22 | DP — | N | N | FORMULATION_OR_PK | — | — | — |
| 8535717 | 2026-02-22 | DP — | N | N | FORMULATION_OR_PK levetiracetam55–90%·750–1600mg rate-controller once-daily tablet | — | — | — |
| 8163306 | 2027-09-03 | DP — | N | N | FORMULATION_OR_PK | — | — | — |
| 8163306 | 2027-09-03 | DP — | N | N | FORMULATION_OR_PK Delivery formulation with an active core, swellable layer, and water-insoluble polymer coat. | — | — | — |
| 8431156 | 2027-10-31 | DP — | N | N | FORMULATION_OR_PK | — | — | — |
| 8431156 | 2027-10-31 | DP — | N | N | FORMULATION_OR_PK Levetiracetam controlled-release formulation with a bilayer core and swellable agent. | — | — | — |
| 8470367 | 2027-10-31 | DP — | N | N | FORMULATION_OR_PK | — | — | — |
| 8470367 | 2027-10-31 | DP — | N | N | FORMULATION_OR_PK Limited to active/rate-controlling/swellable layers, insoluble polymer coat, and a leachable component. | — | — | — |
Regulatory exclusivity
| Code | Start date | End date | Scope | Entire product | All indications | Full coverage date | Combination | Source |
|---|---|---|---|---|---|---|---|---|
| No exclusivity facts are recorded in this product snapshot. | ||||||||
2026-10-10 · CURRENT_SNAPSHOT_NO_RECORD · Historical coverage: NOT_COMPLETE
2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE
Generic approval evidence
| Application / product | Event | Final date | Tentative date | Applicant | Authorized generic | Exact mapping | Source |
|---|---|---|---|---|---|---|---|
| 202958 / 001 | FINAL_APPROVAL · FINAL_APPROVED | 2015-02-25 | — | APOTEX INC | N | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source |
| 200475 / 003 | FINAL_APPROVAL · FINAL_APPROVED | 2015-12-07 | — | AUROBINDO PHARMA USA INC | N | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source |
Market Entry Information
API filings, authorized generics and linked regulatory milestones.
API Master Files & Certifications 0 records
Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.
| API | Holder / manufacturer | Holder country | Filing type | Number | Status | Filed date | Available for reference | Source | Last verified |
|---|---|---|---|---|---|---|---|---|---|
| No master-file or certification records are linked through public manufacturer portfolios. | |||||||||
Authorized Generics 0 records
Authorized generics are shown separately from independent ANDA approvals.
| Application / product | Applicant | Event / status | First marketed | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| No authorized-generic records are linked to this product. | ||||||
Tentative ANDA Approvals 0 records
Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.
| Application / product | Applicant | Event / status | Tentative date | Follow-up final approval | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|---|
| No tentative-approval records are linked to this product. | |||||||
Paragraph IV Challenges 0 records
Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.
| Application / product | Applicant | Event / status | Certification event date | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| No structured Paragraph IV certification events are linked in the available approval evidence. | ||||||
Final ANDA Approvals 2 records
Approval dates do not establish commercial launch. Product mapping is shown for each linked record.
| Application / product | Applicant | Event / status | Final approval date | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| 202958 / 001 | APOTEX INC | FINAL_APPROVAL · FINAL_APPROVED | 2015-02-25 | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source | — |
| 200475 / 003 | AUROBINDO PHARMA USA INC | FINAL_APPROVAL · FINAL_APPROVED | 2015-12-07 | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source | — |
Decision evidence (5)
| Type | Date | Role | Basis | Source |
|---|---|---|---|---|
| PATENT | 2026-02-22 | FTO_TAIL | Limited to levetiracetam 55-90%, a compact high-dose tablet, and permeable coating. | Source |
| PATENT | 2026-02-22 | FTO_TAIL | levetiracetam55–90%·750–1600mg rate-controller once-daily tablet | Source |
| PATENT | 2027-09-03 | FTO_TAIL | Delivery formulation with an active core, swellable layer, and water-insoluble polymer coat. | Source |
| PATENT | 2027-10-31 | FTO_TAIL | Limited to active/rate-controlling/swellable layers, insoluble polymer coat, and a leachable component. | Source |
| PATENT | 2027-10-31 | FTO_TAIL | Levetiracetam controlled-release formulation with a bilayer core and swellable agent. | Source |
Litigation & Settlement History
Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.
No litigation or settlement record currently linked to this product.